About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 787 record(s)
Req # A-2024-000012
Adverse Drug Reactions (ADRs). Report numbers: 001067949, 001069982.Organization: Health Canada
April 2024
Req # A-2024-000017
Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number: 1026516, 1043922. ADRs for HYDROXYCHLOROQUINE. Report numbers: 1024918, 1026702, 1037377.Organization: Health Canada
April 2024
Req # A-2024-000028
Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report numbers: 000709470, 000720165.Organization: Health Canada
April 2024
Req # A-2024-000032
Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.Organization: Health Canada
April 2024
Req # A-2024-000068
Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.Organization: Health Canada
April 2024
Req # N/A
No ATI request closed in AprilOrganization: Office of the Commissioner of Official Languages
April 2024
Req # A-2015-000351
Application submissions and summary for new drug deferiprone licencing. Common Drug Review minutes kept of review process, Canadian Agency fo Drugs and Technologies in Health's (CADTH) interim and final report. Records from January 1, 2012 to January 4, 2016Organization: Health Canada
May 2023
Req # A-2017-001024
The reviewers reports, Module 1 and 2 regarding Information available fromNew Drug Submission (NDS) file - Submission Control No. 189720 AURO-CEFIXIME - DIN 02468689.Organization: Health Canada
May 2023
Req # A-2018-001007
All correspondence between the Health Products and Food Branch with the Canadian Patient Safety Institute related to plain language labeling and/or the self-care framework in 2018.Organization: Health Canada
May 2023
Req # A-2018-001858
Health Canada Reviewer Reports for Breo Ellipta Supplemental New Drug Submission Control Number 213290 Notice of Compliance (NOC) issued 2019-01-09.Organization: Health Canada
May 2023